A Phase 1b study evaluated the safety and effectiveness of the association of durvalumab with ramucirumab, an anti-VEGF receptor-2 (VEGFR-2) IgG1 mAb, in different cohorts of advanced pre-treated cancer patients, including one cohort of 28 HCC subjects (NCT02572687). The gene discussed is KDR; the disease is cancer.